Prolonged suppression of spermatogenesis by oestrogen does not preserve the seminiferous epithelium in procarbazine-treated rats.
We examined the hypothesis that induction of reversible testicular atrophy, subsequent to withdrawal of gonadotrophin support, would alleviate the testicular toxicity of the anti-cancer drug procarbazine. In rats, severe but reversible testicular atrophy and suppression of spermatogenesis were induced 56 days after the subcutaneous insertion of a silastic implant containing oestradiol-17 beta. The effect of this treatment upon the testicular toxicity of four weekly doses of procarbazine (200 mg kg-1) was examined 56 days after the termination of procarbazine/oestrogen treatment. At this time the testicular endocrine and spermatogenic functions were close to normal in rats which has received only oestradiol-17 beta. Procarbazine produced severe testicular atrophy which was associated with azoospermia and destruction of the germinal epithelium. Serum LH and FSH concentrations were raised and were associated with low serum concentrations of both testosterone and androgen-binding protein. The combination of procarbazine with the oestrogen treatment did not change any of the testicular toxicity and in some cases it appeared to be exacerbated. In contrast to these experiments other studies have indicated that the testis can be protected if spermatogenesis is reversibly suppressed by other agents which are also active via the pituitary endocrine system. The data would therefore suggest that protection is achieved either by some testicular change other than withdrawal of pituitary gonadotrophin support or that oestradiol-17 beta has additional activity which is permissive for the development of the testicular toxicity of procarbazine.
Morris
I D
ID
Department of Physiological Sciences, University of Manchester, U.K.
Bardin
C W
CW
Gunsalus
G
G
Ward
J A
JA
D000704:Analysis of Variance; D000727:Androgen-Binding Protein / Q000097:blood; D000818:Animals; D001284:Atrophy; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D004958:Estradiol / Q000494:pharmacology*; D005640:Follicle Stimulating Hormone / Q000097:blood; D006062:Gonadotropins / Q000378:metabolism; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D011344:Procarbazine / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D011863:Radioimmunoassay; D011897:Random Allocation; D051381:Rats; D011919:Rats, Inbred Strains; D012671:Seminiferous Tubules / Q000187:drug effects* / Q000473:pathology; D013076:Sperm Count; D013091:Spermatogenesis / Q000187:drug effects*; D013234:Stem Cells / Q000187:drug effects / Q000473:pathology; D013737:Testis / Q000187:drug effects* / Q000473:pathology
D000727:Androgen-Binding Protein; D006062:Gonadotropins; D011344:Procarbazine; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone